Efficacy and adverse effects of memantine treatment for Alzheimer’s disease from randomized controlled trials

Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease

(2013) David Burke   ANNALS OF INTERNAL MEDICINE

The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors

(2013) George T. Grossberg et al.   CNS DRUGS

A randomized, double-blind, placebo-controlled trial of memantine in a behaviorally enriched sample of patients with moderate-to-severe Alzheimer's disease

(2013) Nathan Herrmann et al.   INTERNATIONAL PSYCHOGERIATRICS

Effects of Memantine on Clinical Ratings, Fluorodeoxyglucose Positron Emission Tomography Measurements, and Cerebrospinal Fluid Assays in Patients With Moderate to Severe Alzheimer Dementia

(2013) Tao Wang et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Efficacy of Memantine for Agitation in Alzheimer’s Dementia: A Randomised Double-Blind Placebo Controlled Trial

(2012) Chris Fox et al.   PLoS One

Memantine Treatment in Patients with Mild to Moderate Alzheimers Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial

(2008) Anton Porsteinsson et al.   Current Alzheimer Research

Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine

(2008) R Schmidt et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY